China April home prices -1.2% YoY Vs -0.7% last month- Reuters

EXE's 20.3% sales CAGR & 46.8% EBITDA margin show strength. At 12x forward P/E, is it a buy?

WVE's weight loss drug shows promise for visceral fat loss, but faces high risk & low revenue. Buy on dip?

CINF's BVPS growth is slow at 4.3%. At 1.5x P/B, it's not a top pick.

Startup funding hits $297B in Q1'26, 2.5x Q4'25! OpenAI & Anthropic lead mega-rounds, boosting valuations.

The US is set to overhaul steel and aluminium tariffs, applying a 25% duty to the full value of finished imports. While simplifying compliance, the change may raise effective costs and boost tariff revenue following recent legal setbacks.

Zoom's 4% billings growth & 98% retention rate signal risks. At 4.7x P/S, it's pricey.

Vertiv (VRT) surges 238% on AI liquid cooling demand. Trades at <10x sales, with 47% EPS growth.